Thymosin Alpha-1
Immune modulation and immune system support
Overview
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally produced by the thymus gland. It is FDA-approved in over 35 countries for hepatitis B/C and as an immune adjuvant. It enhances both innate and adaptive immunity.
Mechanism of Action
Activates dendritic cells and T-cell maturation → enhances TLR signaling → modulates Th1/Th2 balance → increases NK cell activity → promotes MHC class I expression → stimulates IL-2 and IFN-α production.
Benefits
- Enhanced immune surveillance
- Anti-viral activity
- Cancer immunotherapy adjuvant
- Vaccine response enhancement
- Chronic infection support
Dosing Protocol
Half-Life
~2 hours
Duration of pharmacological activity after administration.
Side Effects
- Injection site reactions
- Mild flu-like symptoms (rare)
- Generally very well-tolerated
Stacking Recommendations
Storage & Reconstitution
Lyophilized: 2–8°C stable for 3 years. Reconstituted: 2–8°C, use within 24 hours.
Research Notes
Approved as Zadaxin in 35+ countries. Used as adjunct therapy in hepatitis, cancer, and immunodeficiency. Studied during COVID-19 for immune support. Excellent long-term safety record.
Medical Disclaimer
This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.